Clinical trials: Contraceptive, Oral, Hormonal
Contraception, Female Contraception
A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control
The purpose of the study is to use data from a health care information database to assess the risk of venous thromboembolism (blood clots), myocardial infarction (heart attacks), and stroke among women using a transdermal…
- Trial name
- NCT00377988
- Testing
- Transdermal Contraceptive System, Norgestimate-containing oral contraceptives with EE
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception, Female Contraception
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.
The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Triphasil.
- Trial name
- NCT00236795
- Testing
- norelgestromin + ethinyl estradiol; triphasil.
- Volunteers
- 1,494 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception, Female Contraception
Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with…
- Trial name
- NCT00331071
- Testing
- Monophasic or triphasic Oral contraceptive tablet, Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception, Female Contraception
A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers
The objective of this study is to compare the levels of the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers administered ORTHO EVRA® (a transdermal contraceptive patch)…
- Trial name
- NCT00254865
- Testing
- EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception
YAZ, Oral Contraceptive Registration in China
The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive YAZ in healthy Chinese women.
- Trial name
- NCT00819312
- Testing
- YAZ (SH T00186, BAY86-5300)
- Where
- 17 sites in China, Hong Kong
- Volunteers
- 675 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug Drug Interaction
A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives
The goal of this clinical trial is to learn if drug aprocitentan has an effect on hormonal contraceptives in healthy female volunteers.
- Trial name
- NCT06799884
- Testing
- Ethinyl Estradiol / Levonorgestrel Oral Tablet, Aprocitentan
- Where
- Czechia
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Contraception
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles
The main objective of this trial is to demonstrate the contraceptive efficacy of LPRI424, Additional goals of the trial are to demonstrate the safety and tolerability of LPRI424.
- Trial name
- NCT03945513
- Testing
- LPRI424 (dienogest/ethinylestradiol)
- Where
- United States
- Volunteers
- 1,034 people, healthy volunteers welcome
- Sponsor
- Insud Pharma
Contraceptive, Oral, Hormonal
Cycle Control and Safety of E2-DRSP
The study will be performed as a multi-center, randomized, double-blind, parallel-group trial in fertile women aged between 18 and 35 years inclusive.
- Trial name
- NCT00653614
- Testing
- E2/DRSP (BAY 86-4891) dose 1 (SH T04984E), E2/DRSP (BAY 86-4891) dose 2 (80458739), E2/DRSP (BAY 86-4891) dose 3 (80458755)
- Where
- 25 sites in Germany
- Volunteers
- 635 people
- Sponsor
- Bayer
Healthy Female Volunteers
A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants
The purpose of this study is to evaluate the effect of BMS-986196 when coadministered with combined hormonal oral contraceptives (ethinyl estradiol [EE] and norethindrone [NET]) in healthy female participants.
- Trial name
- NCT05891262
- Testing
- BMS-986196, Loestrin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants
The purpose of the study is to assess the effects of BMS-986278 on Drospirenone (DRSP) and Ethinyl Estradiol (EE) when administered as a combined oral contraceptive in healthy female participants.
- Trial name
- NCT05985590
- Testing
- BMS-986278, Drospirenone/Ethinyl Estradiol
- Where
- Canada
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Contraception, Female Contraception
A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)
The objective of this study is to estimate exposure to the hormones norelgestromin, norgestrel, and ethinyl estradiol in healthy female volunteers across multiple commercial lots of EVRA® (a transdermal contraceptive patch…
- Trial name
- NCT00258063
- Testing
- EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception, Female Contraception
Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
This study uses the PharMetrics and MarketScan US health care insurance claims database to estimate relative risks for non-fatal venous thromboembolism (including cerebral venous sinus thrombosis), ischemic stroke, and acute…
- Conditions
- Contraception, Female Contraception, Fertility Control
- Trial name
- NCT00511784
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dysmenorrhea
To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea
The objective of this study is to investigate the safety and efficacy of (0.02 mg EE as betadex clathrate [β-CDC]) / 3 mg drospirenone (DRSP) for dysmenorrhea.
- Trial name
- NCT02617537
- Testing
- EE20/DRSP(YAZ,BAY86-5300)
- Sponsor
- Bayer
Contraception
Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
To demonstrate the contraceptive efficacy of LF111 . To demonstrate the safety and tolerability of LF111 and assessment of pharmacokinetics of LF111.
- Trial name
- NCT02269241
- Testing
- LF111 (drospirenone)
- Where
- 37 sites in United States
- Volunteers
- 1,552 people, healthy volunteers welcome
- Sponsor
- Laboratories Leon Farma, S.A.
Contraception
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)
This study is a prospective, company-sponsored, non-interventional cohort study of up to 5000 patients in European countries and countries in Middle East who are newly prescribed any available OC.
- Trial name
- NCT00905684
- Testing
- EE30/DRSP (Yasmin, BAY86-5131), Any other OC
- Where
- 13 sites in Albania, Bahrain and 11 more
- Volunteers
- 5,446 people
- Sponsor
- Bayer
Healthy Participants
A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants
The purpose of this study is to evaluate the effect of multiple doses of BMS-986322 on the pharmacokinetics (PK) of Loestrin components in healthy female participants.
- Trial name
- NCT05579574
- Testing
- BMS-986322, Loestrin
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Contraception
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.
The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Mercilon.
- Trial name
- NCT00236782
- Testing
- norelgestromin + ethinyl estradiol; mercilon
- Volunteers
- 1,517 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contraception
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
- Trial name
- NCT05264506
- Testing
- NOMAC-E2 COC
- Where
- 103 sites in United States
- Volunteers
- 3,055 people
- Sponsor
- Organon and Co